Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Llibre |
| Publicat: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Còpia 1 | Disponible |